PHASQ stock falls to USD 0.000001 on PNK 22 Jan 2026: top loser insight
We start market hours on 22 Jan 2026 with PHASQ stock trading at USD 0.000001 on the PNK exchange, making it one of today’s clear top losers. Volume is light at 2,500 shares versus a 50-day average of 22,310, and the quote shows a one-day change of -99.00% from a previous close of USD 0.000100. In this report we explain drivers behind the move, connect recent delisting and bankruptcy signals to price action, and highlight what traders should watch next.
PHASQ stock: market move and immediate drivers
PHASQ stock collapsed to USD 0.000001 during market hours on 22 Jan 2026 after trading flagged as thin and potentially delisted. The company remains in the biotechnology sector and has Chapter 11 history; that combination keeps liquidity low and volatility high. Market participants flagged delisting risk on public sites, and low free float amplified the drop as sellers met few buyers.
Financial snapshot and valuation for PHASQ stock
PhaseBio Pharmaceuticals, Inc. (PHASQ) reports EPS of -2.14 and a negative P/E metric driven by losses; revenue per share TTM is 0.0003684. Key ratios show a current ratio of 1.75 and cash per share of 1.421879, but shareholders’ equity per share is negative at -3.164667. These figures explain why valuation multiples are unreliable and why traditional price targets are scarce.
Recent news, delisting signals and trading context
Public filings and market coverage indicate PhaseBio may face delisting or inactive trading, which has pushed PHASQ stock into top loser status; see MarketBeat coverage and Markets Insider search results for recent notices. Reduced listing status reduces disclosure and market-making, increasing tail risk for holders. MarketBeat report and Markets Insider search provide the latest coverage.
Technicals, trading metrics and Meyka AI grade for PHASQ stock
Trading metrics show a 50-day average price of 0.000236 and 200-day average of 0.000666, with today’s volume at 2,500 shares. Meyka AI rates PHASQ with a score out of 100: 58.84 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector and industry performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
Catalysts, risks and sector positioning for PHASQ stock
Primary upside would come from a successful resolution of restructuring or renewed development progress on PB2452; downside remains near-total loss if the listing status worsens. The stock sits in the Healthcare sector, Biotechnology industry, which outperformed cyclicals last quarter but offers little immediate support for an at-risk microcap. We link the PHASQ profile on Meyka for live monitoring.
Analyst view, liquidity and investor strategy for PHASQ stock
No formal analyst consensus or price-targets are currently available, reflecting limited coverage and delisting risk; average daily volume of 22,310 is deceptive given current thin trades. As a result, we recommend risk-aware approaches: avoid large position sizing, monitor filings closely, and treat PHASQ stock as a high-risk speculative holding rather than a core portfolio name.
Final Thoughts
PHASQ stock is trading at USD 0.000001 on the PNK exchange on 22 Jan 2026 and sits among the session’s top losers due to delisting signals and persistent liquidity constraints. Meyka AI’s forecast model projects USD 0.000 as the baseline scenario over the near term, implying an effective downside that approaches -100.00% from the last quoted price of USD 0.000001; forecasts are model-based projections and not guarantees. Recovery scenarios depend on formal restructuring outcomes or successful clinical progress for PB2452; in a constructive scenario we show illustrative recovery targets: a conservative recovery target of USD 0.001 and a bull scenario target near the 52-week high of USD 0.0399, but those imply multi-fold swings and are speculative. Given the negative equity per share and prior Chapter 11 history, investors should prioritize capital preservation, monitor SEC filings and exchange notices, and limit exposure to what they can afford to lose. Meyka AI provides this analysis as an AI-powered market analysis platform to help track developments in real time.
FAQs
What caused the PHASQ stock drop today?
The drop reflects delisting signals, thin liquidity and legacy Chapter 11 proceedings. Low active volume (about 2,500 shares) amplified selling pressure and pushed the quoted price down to USD 0.000001.
Does Meyka AI provide a price target for PHASQ stock?
Meyka AI’s forecast model projects USD 0.000 as the baseline and offers scenario targets such as USD 0.001 (recovery) and USD 0.0399 (bull). Forecasts are model projections, not guarantees.
Is PHASQ stock a buy during this top losers move?
Given delisting risk, negative equity per share and thin trading, we view PHASQ stock as high risk. Meyka AI grades PHASQ C+ (HOLD); investors should limit position size and watch filings.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
